EUCTR2006-003622-29-IT进行中（未招募）1 期
The ARRIVE Study (Aspirin to Reduce Risk of Initial Vascular Events) - A Randomized, Double-Blind,Placebo Controlled, Multicenter, Parallel Group Study to Assess the Efficacy (Reduction of Cardiovascular Disease Events) and Safety of 100 mg Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease. - ARRIVE
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- BAYER
- 入组人数
- 12,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males aged 50 years and above with 2 or 3 risk factors Male Risk Factors Males aged 60 and above Elevated cholesterol (Tchol>200 mg/dL or LDL>130 mg/dL; as measured at screening) irrespective of current treatment Current smoking*: defined as any cigarette smoking in the past 12 months (*smoking cannot be the sole risk factor for males aged 60 and above) Low HDL cholesterol (HDL<40 mg/dL; as measured at screening) Elevated blood pressure (SBP>140 mmHg; as measured at screening) Currently on any medication to treat high blood pressure Positive family history of early CHD (a first-degree relative [father, mother, brother, sister, son, daughter] suffered a heart attack [myocardial infarction] before the age of 60 years) 2. Females aged 60 and above with 3 or more risk factors Female Risk Factors Elevated cholesterol (Tchol>240 mg/dL or LDL>160 mg/dL; as measured at screening) Current smoking: defined as any cigarette smoking in the past 12 months Low HDL cholesterol (HDL<40 mg/dL; as measured at screening) Elevated blood pressure (SBP>140 mmHg; as measured at screening) Currently on any medication to treat high blood pressure Positive family history of early CHD (a first-degree relative [father, mother, brother, sister, son, daughter] suffered a heart attack [myocardial infarction] before the age of 60 years) 3. An understanding and willingness to comply with trial procedures and has given written informed consent to participate in the trial
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Clinical history of CVD, MI, stroke, coronary artery angioplasty or stenting,coronary artery bypass graft, relevant arrhythmias, or congestive heart failure 2. Patients who are at higher than moderate risk on the basis of: a) their diabetes status (i.e. those with Type I or Type II diabetes actively treated with drug therapy) b) other factors known to the investigator (e.g. a male patient over 60 years of age with 4 or more risk factors) c) the currently used national risk score 3. Any medical condition, or psychiatric or substance abuse disorder, that, in the opinion of the investigator, is likely to affect the patient?s ability to complete the study or precludes the patient?s participation in the study 4. Lactating women or women of childbearing potential 5. Known increased risk of bleeding, e.g., gastric or duodenal ulcer, genitourinary causes or other bleeding disorders. 6. Known/diagnosed reflux esophagitis. 7. Moderately impaired renal function based on the clinical judgment of the investigator. 8. Severe liver disease or damage based on the clinical judgment of the investigator. 9. A history of asthma induced by administration of salicylates or substances with a similar action, notably NSAIDs 10. History of hypersensitivity or drug allergy to acetylsalicylic acid 11. A definite indication for acetylsalicylic acid therapy, other anti-platelet drug, or anticoagulant in the opinion of the physician 12. Chronic, frequent (> 5 days/month) use of NSAIDs, COX-2 inhibitors or metamizole (acetaminophen/paracetamol and other non NSAID pain medications will be permitted) 13. Current participation in any other trials involving investigational products within 30 days prior to the Screening Visit.
研究者
相似试验
进行中（未招募）
1 期
The ARRIVE Study (Aspirin to Reduce Risk of Initial Vascular Events) - A Randomized, Double-Blind, Placebo Controlled, Multicenter, Parallel Group Study to Assess the Efficacy (Reduction of Cardiovascular Disease Events) and Safety of 100 mg Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease - ARRIVEPatients at moderate risk of CHD events (10-20% 10-year CHD riskapproximately 30% 10-year risk of CVD events based on the underlyingassumption at study start).MedDRA version: 19.0Level: LLTClassification code 10072760Term: Transient ischemic attackSystem Organ Class: 100000004852MedDRA version: 19.0Level: LLTClassification code 10042244Term: StrokeSystem Organ Class: 100000004852MedDRA version: 19.0Level: LLTClassification code 10046251Term: Unstable anginaSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 19.0Level: PTClassification code 10028596Term: Myocardial infarctionSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 19.0Level: PTClassification code 10049993Term: Cardiac deathSystem Organ Class: 10018065 - General disorders and administration site conditionsEUCTR2006-003622-29-DEBayer AG12,000
进行中（未招募）
1 期
The ARRIVE Study (Aspirin to Reduce Risk of Initial Vascular Events) - A Randomized, Double-Blind, Placebo Controlled, Multicenter, Parallel Group Study to Assess the Efficacy (Reduction of Cardiovascular Disease Events) and Safety of 100 mg Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease - ARRIVEEUCTR2006-003622-29-GBBayer AG12,000
进行中（未招募）
1 期
The ARRIVE Study (Aspirin to Reduce Risk of Initial Vascular Events) - A Randomized, Double-Blind, Placebo Controlled, Multicenter, arallel Group Study to Assess the Efficacy (Reduction of Cardiovascular Disease Events) and Safety of 100 mg Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease - ARRIVEEUCTR2006-003622-29-IEBayer Consumer Care AG12,000
进行中（未招募）
1 期
Estudio ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events, aspirina para reducir el riesgo de accidentes vasculares iniciales) – Estudio aleatorizado, doble ciego, controlado con placebo, multicéntrico y de grupos paralelos para evaluar la eficacia (reducción de los acontecimientos de enfermedad cardiovascular) y la seguridad de 100 mg ácido de acetilsalicílico con recubrimiento entérico en pacientes con riesgo moderado de sufrir enfermedad cardiovascular. - ARRIVEEUCTR2006-003622-29-ESBayer HealhCare AG12,000
进行中（未招募）
1 期
Investigating the Role of Early Low-dose Aspirin in DiabetesEUCTR2018-000770-29-IEThe Rotunda Hospital360